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S
 
-Nitrosoglutathione (GSNO), a naturally occurring constituent of
 
airway lining fluid, enhances ciliary motility, relaxes airway smooth
muscle, inhibits airway epithelial amiloride-sensitive sodium trans-
port, and prevents pathogen replication. Remarkably, airway levels
of GSNO are low in patients with cystic fibrosis (CF). We hypothe-
sized that replacement of airway GSNO would improve gas ex-
change in CF. In a double-blind, placebo controlled study, we ad-
ministered 0.05 ml/kg of 10 mM GSNO or phosphate buffered
saline by aerosol to patients with CF and followed oxygen satura-
tion, spirometry, respiratory rate, blood pressure, heart rate, and
expired nitric oxide (NO). Nine patients received GSNO and 11
placebo. GSNO inhalation was associated with a modest but sus-
tained increase in oxygen saturation at all time points. Expired NO
 
increased in the low ppb range with GSNO treatment, peaking at 5
minutes but remaining above baseline at 30 minutes. There were
no adverse effects. We conclude that GSNO is well tolerated in pa-
tients with CF and improves oxygenation through a mechanism
that may be independent of free NO. Further, GSNO breakdown in-
creases expired NO. We suggest that therapy aimed at restoring
endogenous GSNO levels in the CF airway may merit study.
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S
 
-Nitrosoglutathione (GSNO) is an endogenous nitrogen oxide
present in high concentrations in the extracellular fluids of the
lung and brain (1, 2). It has a bioactivity profile that is well
suited for maintaining airway homeostasis and, in many cases,
distinct from that of its breakdown product, nitric oxide (NO)
(3–5). In particular, GSNO in concentrations present in the
airways relaxes airway smooth muscle (1), improves airway
ciliary motility (6), inhibits airway epithelial amiloride-sensi-
tive sodium transport while activating calcium-dependent epi-
thelial chloride transport (7, 8), promotes neutrophilic apop-
tosis (9), and has antimicrobial effects (10–12). Additionally,
it has recently been observed to increase cellular expression
and maturation of the common mutant form of the cystic fi-
brosis transmembrane regulation protein (CFTR), 
 

 
F508, in
physiologically relevant concentrations (13). There is increas-
ing evidence that GSNO metabolism is regulated indepen-
 
dently of NO and other 
 
S
 
-nitrosothiols (SNOs) (5, 14, 15).
Levels of GSNO tend to be low in the cystic fibrosis (CF)
airway (16). Depletion of GSNO may reflect the decreased
levels of glutathione (17, 18), decreased airway epithelial NO
synthase (NOS) expression (19, 20) and/or accelerated catabo-
lism of GSNO (5, 14) that may be features of the disease.
GSNO depletion could contribute to the pathophysiology of
CF lung disease by impairing mucus clearance, aggravating
airflow obstruction, and predisposing to chronic airway neu-
trophilic inflammation. Here, we report that aerosolized re-
placement therapy with GSNO is well tolerated and results in
a modest improvement in gas exchange in patients with CF.
 
METHODS
 
Subjects
 
Subjects 10–50 years old were recruited from CF clinic if they had a
sweat chloride concentration greater than 60 mEq/L and chronic
bronchiectasis with moderate obstructive disease. Subjects were ex-
cluded who had a room air oxygen saturation of less than 90%, who
were hypotensive, or who had a history of gastrointestinal bleeding,
massive hemoptysis, or any hemoptysis within the preceding month.
The protocol was reviewed and approved by the institutional Human
Investigation Committee.
 
Experimental Protocol
 
After providing informed consent, subjects were sequentially assigned
in a blinded fashion by the research pharmacist to receive either
GSNO or placebo using a prerandomized code. GSNO (10 mM) was
prepared by nitrosation of glutathione, assayed for purity as previ-
ously described (1, 21, 22) and brought to pH 7.0 in 10 mM and phos-
phate buffered saline (PBS). Control subjects received 10 mM PBS
alone. Both GSNO and PBS were filtered for sterilization (0.22 
 

 
m),
cultured to confirm sterility in accordance with Food and Drug Ad-
ministration guidelines (BioWhittaker, Walkersville, MD), and stored
at 
 

 
80
 

 
 C in foil-covered aliquots. After measurement of baseline ox-
ygen saturation, heart rate, blood pressure, respiratory rate, spirome-
try, and expired nitric oxide concentration (FE
 
NO
 
), subjects received
0.05 ml/kg of GSNO or PBS, up to a maximum 3.0 ml, by nebulizer
(Devilbis, Somerset, PA). This dose was calculated to increase the air-
way epithelial lining fluid concentration from undetectable (16) to a
physiologically relevant and pharmacologically active concentration
(1) (
 
see
 
 online data supplement). Sputum was collected for 30 minutes
before and 30 minutes after treatment. Vital signs, oxygen saturation
and FE
 
NO
 
 were measured at 5, 10, 20, and 30 minutes after completion
of the treatment. Oxygen saturation values accepted were those that
were stable for 10 seconds. Spirometry was measured at 10 and 30
minutes after treatment (Sensorimedics, Yorba Linda, CA).
 
Chemical Analysis
 
GSNO was analyzed for contaminants as previously described using
mass spectrometry (22) and spectrophotometric analysis for ammo-
nium (NH
 
4
 

 
) (23).
 
Expired NO Measurement
 
Nitric oxide concentrations were measured by chemiluminescence
(Sievers Instruments, Boulder, CO). Single breath vital capacity off-line
collections were made using an 8.1-L Tedlar gas sampling bag (Fisher
Scientific, Pittsburgh, PA) as previously described (24, 25). As noted
in the American Thoracic Society guidelines for FE
 
NO
 
 measurement,
this procedure allows for measurement at clinic sites remote from the
chemiluminescence analyzer (26) and is highly reproducible (24).
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Statistical Analysis
 
Means at multiple time points were compared by analysis of variance
(ANOVA) and, where appropriate, by 
 
t
 
 test or—for nonparametri-
cally distributed sets—by Rank Sum Testing. A value of p 
 

 
 0.05 was
considered significant. Data are presented as mean 
 

 
 SEM.
 
RESULTS
 
Nine patients were randomized to receive GSNO and 11 to re-
ceive PBS. They did not differ with respect to age, baseline vi-
tal capacity or forced expiratory volume at one second (FEV
 
1
 
)
(as either absolute value or percent predicted), FEV
 
1
 
/forced
vital capacity (FVC) ratio, vital signs, or oxygen saturation
(Table 1).
The GSNO used in these experiments contained no NH
 
4
 

 
,
peroxynitrite, nitrate, or oxidized glutathione (GSSG), that is,
had not decomposed (Figure 1); solutions contained less than
10% of the reactant, GSH, which, given as an aerosol, would
be a predicted increase in airway GSH concentration by 10
 

 
M, or 
 

 
 1% of that normally present in the airway (1).
Oxygen saturation increased at all time points in the
GSNO-treated group. The change in saturation from baseline
ranged from 0.89 
 

 
 0.51 to 1.44 
 

 
 0.58% for GSNO, greater at
each time point than the change in saturation for the PBS
group (range, 
 

 
0.73 
 

 
 0.3 to 
 

 
0.273 
 

 
 0.43); p 
 

 
 0.01 by
ANOVA (Figure 2). The difference between the GSNO-
treated group and the PBS group remained robust at 30 min-
utes (change in saturation from baseline 
 
	
 
 1.33 
 

 
 0.53% for
GSNO, versus 
 

 
0.36 
 

 
 0.36% for the PBS group; p 
 

 
 0.05).
Oxygen saturation values did not change significantly from
baseline following PBS inhalation alone (p 
 
	
 
 NS, ANOVA).
GSNO was well tolerated in all subjects. Spirometry did not
change at any time point (Figure 3). Sputum production (p 
 
	
 
NS) and vital signs also did not change (Figure 3).
Consistent with previous observations (25), baseline ex-
pired NO concentrations were somewhat low in CF compared
with published normal data (24, 25). Inhaled GSNO treatment
dramatically increased FE
 
NO
 
 at five minutes (change in [NO]
from baseline 
 
	
 
 7.5 
 

 
 3.6 ppb, versus 
 

 
0.27 
 

 
 0.48 ppb for
PBS; p 
 

 
 0.001), demonstrating directly that GSNO break-
down in the airway increases FE
 
NO
 
. Expired NO levels fell over
the first 20 minutes, but were still higher than those in the PBS
group at 30 minutes (change in [NO] from baseline 
 
	
 
 1.69 
 

 
0.68 ppb versus 0 
 

 
 0.37 ppb for PBS; p 
 

 
 0.05) (Figure 4).
The change in [NO] was unrelated to the change in oxygen
saturation.
 
DISCUSSION
 
The function-regulating activities of SNOs include a diversity
of effects that oppose the major pathophysiologic features of
airway disease in CF. Remarkably, levels of SNOs in general,
and GSNO in particular, are relatively low in the bronchoalve-
olar lavage fluid of patients with CF (16), possibly as a result
of decreased airway epithelial NOS expression (19, 20) and/or
decreased glutathione levels (17, 18). It has also been shown
that airway inflammation is associated with increased GSNO
catabolism (14, 27), and thus accelerated breakdown may con-
tribute to low SNO levels.
Both NO and GSH have actions that should promote lung
health in patients with CF. However, long-term therapeutic
administration of NO is impractical, and short-term use does
not appear to be of benefit (28). This may be because of ad-
verse effects of ppm NO concentrations—particularly in the
oxidative environment of the CF airway—counterbalancing
its potential salutary effects (29). Furthermore, although GSH
inhalation may have beneficial biochemical effects in the CF
airway, in part because of disorders of redox regulation and
antioxidant genes may contribute to the pathophysiology of
airway injury (30, 31), physiological benefit has not be demon-
strated (32). Indeed, GSH given by nebulizer has been re-
ported to cause bronchoconstriction (33), and long-term use
of the cell permeable glutathione analog, N-acetylcysteine, by
 
TABLE 1. SUBJECT CHARACTERISTICS AT STUDY ENTRY
 
GSNO Group Placebo Group p
Age, yr 16.1 
 

 
 1.44 19.9 
 

 
 3.45 0.34
Respiratory rate, minute
 

 
1
 
28.0 
 

 
 5.22 24.4 
 

 
 3.89 0.58
Heart rate, minute
 

 
1
 
99.0 
 

 
 6.55 88.9 
 

 
 6.18 0.28
Systolic blood pressure, mm Hg 105.8 
 

 
 3.79 110.5 
 

 
 3.06 0.34
Diastolic blood pressure, mm Hg 66.1 
 

 
 3.68 70.4 
 

 
 2.63 0.35
Oxygen saturation, % 94.9 
 

 
 0.82 96.0 
 

 
 0.73 0.33
Expired NO, ppb 6.74 
 

 
 0.94 5.04 
 

 
 0.57 0.12
FVC, L 2.59 
 

 
 0.27 2.97 
 

 
 0.39 0.45
FVC, % 71.5 
 

 
 6.15 80.8 
 

 
 6.98 0.35
FEV
 
1
 
, L 2.01 
 

 
 0.26 1.92 
 

 
 0.31 0.83
FEV
 
1
 
, % 60.5 
 

 
 7.7 59.3 
 

 
 8.02 0.916
FEF
 
25–75
 
, L/second 1.77 
 

 
 0.46 1.35 
 

 
 0.30 0.45
Figure 1. GSNO was assayed
for purity using liquid chroma-
tography–mass spectrometry.
No impurities were present in
the mass chromatogram except
for glutathione (GSH). The spec-
trum of the major peak (9.42
minutes) is shown. Note that
the instrument is not sensitive
below a m/z of 50, but sepa-
rate spectrophotometric anal-
ysis revealed no NH4
.
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nebulization has been disappointing (34). By contrast, GSNO
is an attractive therapeutic candidate: (
 
1
 
) it is endogenously
formed in high concentrations; (
 
2
 
) it is potentially more po-
tent, less toxic, and longer lived than NO, and thus more prac-
tical to deliver; (
 
3
 
) it seems to produce only physiological (nM)
concentrations of NO (Figure 4), potentially preventing toxic-
ity; and (
 
4
 
) it is deficient in CF patients. Here, we demonstrate
that aerosolized administration of GSNO to patients with CF
is well tolerated and results in a modest improvement in oxy-
 
genation. These data suggest that GSNO may improve gas ex-
change by a mechanism independent of NO and GSH effects.
GSNO was originally described in the airways as an endog-
enous bronchodilator, two log orders more potent than theo-
phylline and present in the normal airway in concentrations
sufficient to relax human airway smooth muscle (1). Subse-
quently, SNOs have been shown to be well tolerated and
cause bronchodilatation in animal models (35), to increase air-
way ciliary beat frequency (6), and to have the potential to
augment airway hydration by inhibiting amiloride sensitive so-
dium transport (7) and increasing chloride transport (8). GSNO
also has antimicrobial effects, perhaps the most relevant of
which is inhibition of viral replication through 
 
S
 
-nitrosylation
of cysteine proteases (10, 11).
Theoretical risks of administering GSNO include hypoten-
sion and bleeding. However, it should be noted that GSNO
does not cause significant hypotension in rats or humans when
given parenterally (36–38), and aerosolized GSNO had no sys-
temic hemodynamic effects. None of our patients experienced
bleeding or developed petechiae, although we were careful to
exclude patients with a history of airway or gastrointestinal
bleeding. It is also possible that GSNO metabolites such as
NO and NH
 
4
 

 
 could have adverse effects on the CF airway (29,
39–41), though measured NO and predicted NH
 
4
 

 
 (low 
 

 
M)
concentrations were log orders below those shown to be phys-
iologically or pathologically relevant (39, 41, 42).
It had been widely held that expired NO is a marker of air-
way NOS activity. However, recent studies in patients with
asthma have indicated that expired NO is at least partly de-
rived from metabolism of airway lining constituents (14, 27,
43). These studies made several puzzling observations that may
be reconciled by the proposal that GSNO is metabolized to
NO within the airway (3, 14, 27). The increase in expired NO
(hypernitrosopnea [24]) we have observed following GSNO
administration demonstrates directly that airway GSNO break-
down can influence NO concentrations in expired breath.
The half-life of GSNO in solution will vary with redox state,
nature of the redox cofactors, and the concentration of nu-
cleophiles, but it is generally on the order of hours (14, 29, 32,
40, 44). Several enzymes have been reported to breakdown
GSNO, as recently reviewed (5, 14, 15). Inhibition of such
metabolic activity might represent a new therapeutic ap-
proach in CF. Of note, NO itself is generally regarded as a mi-
nor product of organic and inorganic GSNO catabolism (5, 14,
15, 29, 40).
GSNO did not break down before administration. There
were no major catabolic products, NH
 
4
 

 
 and GSSG (15, 40),
or minor products such as nitrate or peroxynitrite, in the prep-
aration. Small (
 

 
M) quantities of reactant (GSH) could be de-
tected, but these would raise endogenous ELF concentrations
of GSH less than 1% (1).
Figure 2. GSNO inhalation re-
sults in improved oxygenation
in CF. Oxygen saturation im-
proved at all time points in the
GSNO-treated group (solid line;
n 	 9) compared with the pla-
cebo-treated group (dashed line;
n 	 11; p  0.01 by ANOVA).
Data are presented as mean  SE.
Figure 3. GSNO is well tolerated in CF. GSNO inhalation (circles; n 	
9) did not cause a significant change in (A) respiratory rate; (B ) heart
rate; (C ) systolic blood pressure; (D) diastolic blood pressure; (E)
forced vital capacity; or (F ) forced expiratory volume at 1 second—at
any time point after inhalation when compared with control (PBS in-
halation) (squares, n 	 11; p 	 NS by ANOVA). Data are presented as
mean  SE.
Figure 4. GSNO break-
down increases expired NO.
Changes in expired NO in
the subjects receiving GSNO
(circles; n 	 9) were higher
than those in the placebo
group (squares; n 	 11) at
each time point (p  0.001
by ANOVA). The FENO of
GSNO-treated patients re-
mained substantially in-
creased relative to that in the
PBS group for 30 minutes
(p  0.05). Data are pre-
sented as mean  SE.
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Improvements in oxygenation were unrelated to changes in
expired NO gas concentrations. Further, the maximum FENO
did not exceed that seen in asthma (on the order of 15–20 ppb)
(24, 25), a condition commonly associated with ventilation/
perfusion mismatch and hypoxemia. NO concentrations a 1,000-
fold higher, which may have local and systemic toxicity, are re-
quired to achieve a meaningful degree of pulmonary vascular
smooth muscle relaxation in the therapeutic setting (3, 42, 45).
Of note, even these higher concentrations of NO gas delivered
to the CF airway do not improve oxygenation (28). Taken to-
gether, these observations suggest that GSNO does not im-
prove oxygenation simply through release of NO. Support for
this contention can be found in (1) the differing propensities
of NO and GSNO to S-nitrosylate ion channels such as those
that regulate airway smooth muscle tone and the viscosity of
secretions (44, 46, 47); (2) the immunohistochemical (48) and
chemical (1, 45) data establishing that S-nitrosylation reac-
tions occur in airways; and (3) a recent study showing that in-
haled ethyl nitrite, an S-nitrosylating agent that releases little
NO, causes more potent and sustained improvement in oxy-
genation following lung injury than does NO (45). Of note,
SNOs may increase both peripheral oxygen delivery (49) and
the ventilatory response to hypoxia (22) through erythrocyte-
mediated mechanisms—in addition to improving oxygen uptake
in the lungs—as recently reviewed (50). These observations may
form the theoretical basis for understanding improvements in
oxygenation associated with GSNO inhalation.
In summary, we report that replacement of endogenous
GSNO in patients with CF is well tolerated acutely and results
in a modest improvement in oxygenation. Additionally, we
demonstrate that GSNO breakdown directly affects concen-
trations of NO measured in expired air. Our data suggest that
more in-depth studies of the pulmonary and nonpulmonary
effects of GSNO or related compounds could possibly lead to
therapies of benefit to patients with CF.
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